Informations

In a recent academic session, Professor David F. McDermott from Beth Israel Deaconess Medical Center presented the latest findings from Part 1 of the LITESPARK-024 study. This trial evaluated the safety and preliminary efficacy of the HIF-2α inhibitor belzutifan in combination with the CDK4/6 inhibitor palbociclib in patients with previously treated advanced clear cell renal…

At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.

At a recent academic conference, Professor Ben Tran from the Peter MacCallum Cancer Centre and the University of Melbourne presented the preliminary results of the CLIMATE study (ANZUP 1906). This prospective cohort study aimed to evaluate the clinical utility of microRNA-371a-3p (miR-371) as a marker for minimal residual disease (MRD) in predicting relapse in patients…

At a recent international oncology academic conference, Professor Avivit Peer presented the latest findings from the KEYMAKER-U04 Substudy 04B. This study investigated the efficacy and safety of adding an anti-LAG-3 or anti-TIGIT antibody to the standard-of-care enfortumab vedotin (EV) plus pembrolizumab backbone as a first-line treatment for advanced urothelial carcinoma (UC). Our editorial team has…

At a recent international academic symposium, Dr. Aly-Khan A. Lalani from McMaster University presented the primary results of the CYTOSHRINK study (Abstract 416). This randomized Phase II trial evaluated the efficacy and safety of cytoreductive stereotactic body radiotherapy (SBRT) combined with nivolumab plus ipilimumab (Nivo+Ipi) in patients with treatment-naïve metastatic clear cell renal cell carcinoma…

With the continuous increase in the global incidence of prostate cancer and the variation in disease progression risk driven by tumor heterogeneity, accurate risk stratification is crucial for optimizing clinical treatment decisions. At a recent international oncology conference, Dr. Anna Clare Wilkins from The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation…

01 Study Design: Strategic Combination with Bone Protection The randomized 1:1 trial enrolled 446 mCRPC patients with bone metastases (asymptomatic or mildly symptomatic, lacking visceral metastases). Patients received either enzalutamide…

At a recent major oncology conference, Professor Fred Saad from the University of Montreal Hospital Center delivered an oral presentation on the latest findings of the PANTHER study (Abstract 19). This study reported the first-in-human phase 1 dose-escalation results of a novel PSMA-targeted radioligand therapy (RLT)—Actinium-225-PSMA-trillium (225Ac-PSMA-trillium)—in patients with metastatic castration-resistant prostate cancer (mCRPC), bringing…